Pegylated arginine deiminase treatment of patients with metastatic melanoma

Results from phase I and II studies

Paolo A. Ascierto, Stefania Scala, Giuseppe Castello, Antonio Daponte, Ester Simeone, Alessandro Ottaiano, Gerardo Beneduce, Vincenzo De Rosa, Francesco Izzo, Maria Teresa Melucci, C. Mark Ensor, Archie W. Prestayko, Frederick W. Holtsberg, John S. Bomalaski, Mike A. Clark, Niramol Savaraj, Lynn G. Feun, Theodore Logan

Research output: Contribution to journalArticle

161 Citations (Scopus)

Abstract

Purpose: Individuals with metastatic melanoma have a poor prognosis. Many human melanomas are auxotrophic for arginine, and arginine is not an essential amino acid in humans. We hypothesized that this auxotrophy may be therapeutically exploited. A novel amino acid-degrading enzyme (arginine deiminase) conjugated to polyethylene glycol (ADI-SS PEG 20,000 mw) was used to lower plasma arginine in individuals with metastatic melanoma. Patients and Methods: Two cohort dose-escalation studies were performed. A phase I study in the United States enrolled 15 patients, and a phase I to II study in Italy enrolled 24 patients. The Italian patients also received two subsequent cycles of treatment, each consisting of four once-weekly injections of 160 U/m 2. The goals of these studies were to determine pharmacokinetics (PK), pharmacodynamics (PD), safety, and the antitumor activity of ADI-SS PEG 20,000 mw. Results: PK and PD studies indicated that a dose of 160 U/m 2 lowered plasma arginine from a resting level of approximately 130 μmol/L to less than 2 μmol/L for at least 7 days; nitric oxide levels also were lowered. There were no grade 3 or 4 toxicities directly attributable to the drug. Six of 24 phase I to II patients responded to treatment (five partial responses and one complete response; 25% response rate) and also had prolonged survival. Conclusion: Elimination of all detectable plasma arginine in patients with metastatic melanoma was well tolerated and may be effective in the treatment of this cancer. Further testing of ADI-SS PEG 20,000 mw in a larger population of individuals with metastatic melanoma is warranted.

Original languageEnglish (US)
Pages (from-to)7660-7668
Number of pages9
JournalJournal of Clinical Oncology
Volume23
Issue number30
DOIs
StatePublished - 2005

Fingerprint

Melanoma
Arginine
Therapeutics
Pharmacokinetics
Essential Amino Acids
Italy
ADI PEG20
Nitric Oxide
Safety
Amino Acids
Injections
Survival
Enzymes
Pharmaceutical Preparations
Population
polyethylene glycol bis(succinimidyl succinate)
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pegylated arginine deiminase treatment of patients with metastatic melanoma : Results from phase I and II studies. / Ascierto, Paolo A.; Scala, Stefania; Castello, Giuseppe; Daponte, Antonio; Simeone, Ester; Ottaiano, Alessandro; Beneduce, Gerardo; De Rosa, Vincenzo; Izzo, Francesco; Melucci, Maria Teresa; Ensor, C. Mark; Prestayko, Archie W.; Holtsberg, Frederick W.; Bomalaski, John S.; Clark, Mike A.; Savaraj, Niramol; Feun, Lynn G.; Logan, Theodore.

In: Journal of Clinical Oncology, Vol. 23, No. 30, 2005, p. 7660-7668.

Research output: Contribution to journalArticle

Ascierto, PA, Scala, S, Castello, G, Daponte, A, Simeone, E, Ottaiano, A, Beneduce, G, De Rosa, V, Izzo, F, Melucci, MT, Ensor, CM, Prestayko, AW, Holtsberg, FW, Bomalaski, JS, Clark, MA, Savaraj, N, Feun, LG & Logan, T 2005, 'Pegylated arginine deiminase treatment of patients with metastatic melanoma: Results from phase I and II studies', Journal of Clinical Oncology, vol. 23, no. 30, pp. 7660-7668. https://doi.org/10.1200/JCO.2005.02.0933
Ascierto, Paolo A. ; Scala, Stefania ; Castello, Giuseppe ; Daponte, Antonio ; Simeone, Ester ; Ottaiano, Alessandro ; Beneduce, Gerardo ; De Rosa, Vincenzo ; Izzo, Francesco ; Melucci, Maria Teresa ; Ensor, C. Mark ; Prestayko, Archie W. ; Holtsberg, Frederick W. ; Bomalaski, John S. ; Clark, Mike A. ; Savaraj, Niramol ; Feun, Lynn G. ; Logan, Theodore. / Pegylated arginine deiminase treatment of patients with metastatic melanoma : Results from phase I and II studies. In: Journal of Clinical Oncology. 2005 ; Vol. 23, No. 30. pp. 7660-7668.
@article{64207729d410422b945009123874cf30,
title = "Pegylated arginine deiminase treatment of patients with metastatic melanoma: Results from phase I and II studies",
abstract = "Purpose: Individuals with metastatic melanoma have a poor prognosis. Many human melanomas are auxotrophic for arginine, and arginine is not an essential amino acid in humans. We hypothesized that this auxotrophy may be therapeutically exploited. A novel amino acid-degrading enzyme (arginine deiminase) conjugated to polyethylene glycol (ADI-SS PEG 20,000 mw) was used to lower plasma arginine in individuals with metastatic melanoma. Patients and Methods: Two cohort dose-escalation studies were performed. A phase I study in the United States enrolled 15 patients, and a phase I to II study in Italy enrolled 24 patients. The Italian patients also received two subsequent cycles of treatment, each consisting of four once-weekly injections of 160 U/m 2. The goals of these studies were to determine pharmacokinetics (PK), pharmacodynamics (PD), safety, and the antitumor activity of ADI-SS PEG 20,000 mw. Results: PK and PD studies indicated that a dose of 160 U/m 2 lowered plasma arginine from a resting level of approximately 130 μmol/L to less than 2 μmol/L for at least 7 days; nitric oxide levels also were lowered. There were no grade 3 or 4 toxicities directly attributable to the drug. Six of 24 phase I to II patients responded to treatment (five partial responses and one complete response; 25{\%} response rate) and also had prolonged survival. Conclusion: Elimination of all detectable plasma arginine in patients with metastatic melanoma was well tolerated and may be effective in the treatment of this cancer. Further testing of ADI-SS PEG 20,000 mw in a larger population of individuals with metastatic melanoma is warranted.",
author = "Ascierto, {Paolo A.} and Stefania Scala and Giuseppe Castello and Antonio Daponte and Ester Simeone and Alessandro Ottaiano and Gerardo Beneduce and {De Rosa}, Vincenzo and Francesco Izzo and Melucci, {Maria Teresa} and Ensor, {C. Mark} and Prestayko, {Archie W.} and Holtsberg, {Frederick W.} and Bomalaski, {John S.} and Clark, {Mike A.} and Niramol Savaraj and Feun, {Lynn G.} and Theodore Logan",
year = "2005",
doi = "10.1200/JCO.2005.02.0933",
language = "English (US)",
volume = "23",
pages = "7660--7668",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "30",

}

TY - JOUR

T1 - Pegylated arginine deiminase treatment of patients with metastatic melanoma

T2 - Results from phase I and II studies

AU - Ascierto, Paolo A.

AU - Scala, Stefania

AU - Castello, Giuseppe

AU - Daponte, Antonio

AU - Simeone, Ester

AU - Ottaiano, Alessandro

AU - Beneduce, Gerardo

AU - De Rosa, Vincenzo

AU - Izzo, Francesco

AU - Melucci, Maria Teresa

AU - Ensor, C. Mark

AU - Prestayko, Archie W.

AU - Holtsberg, Frederick W.

AU - Bomalaski, John S.

AU - Clark, Mike A.

AU - Savaraj, Niramol

AU - Feun, Lynn G.

AU - Logan, Theodore

PY - 2005

Y1 - 2005

N2 - Purpose: Individuals with metastatic melanoma have a poor prognosis. Many human melanomas are auxotrophic for arginine, and arginine is not an essential amino acid in humans. We hypothesized that this auxotrophy may be therapeutically exploited. A novel amino acid-degrading enzyme (arginine deiminase) conjugated to polyethylene glycol (ADI-SS PEG 20,000 mw) was used to lower plasma arginine in individuals with metastatic melanoma. Patients and Methods: Two cohort dose-escalation studies were performed. A phase I study in the United States enrolled 15 patients, and a phase I to II study in Italy enrolled 24 patients. The Italian patients also received two subsequent cycles of treatment, each consisting of four once-weekly injections of 160 U/m 2. The goals of these studies were to determine pharmacokinetics (PK), pharmacodynamics (PD), safety, and the antitumor activity of ADI-SS PEG 20,000 mw. Results: PK and PD studies indicated that a dose of 160 U/m 2 lowered plasma arginine from a resting level of approximately 130 μmol/L to less than 2 μmol/L for at least 7 days; nitric oxide levels also were lowered. There were no grade 3 or 4 toxicities directly attributable to the drug. Six of 24 phase I to II patients responded to treatment (five partial responses and one complete response; 25% response rate) and also had prolonged survival. Conclusion: Elimination of all detectable plasma arginine in patients with metastatic melanoma was well tolerated and may be effective in the treatment of this cancer. Further testing of ADI-SS PEG 20,000 mw in a larger population of individuals with metastatic melanoma is warranted.

AB - Purpose: Individuals with metastatic melanoma have a poor prognosis. Many human melanomas are auxotrophic for arginine, and arginine is not an essential amino acid in humans. We hypothesized that this auxotrophy may be therapeutically exploited. A novel amino acid-degrading enzyme (arginine deiminase) conjugated to polyethylene glycol (ADI-SS PEG 20,000 mw) was used to lower plasma arginine in individuals with metastatic melanoma. Patients and Methods: Two cohort dose-escalation studies were performed. A phase I study in the United States enrolled 15 patients, and a phase I to II study in Italy enrolled 24 patients. The Italian patients also received two subsequent cycles of treatment, each consisting of four once-weekly injections of 160 U/m 2. The goals of these studies were to determine pharmacokinetics (PK), pharmacodynamics (PD), safety, and the antitumor activity of ADI-SS PEG 20,000 mw. Results: PK and PD studies indicated that a dose of 160 U/m 2 lowered plasma arginine from a resting level of approximately 130 μmol/L to less than 2 μmol/L for at least 7 days; nitric oxide levels also were lowered. There were no grade 3 or 4 toxicities directly attributable to the drug. Six of 24 phase I to II patients responded to treatment (five partial responses and one complete response; 25% response rate) and also had prolonged survival. Conclusion: Elimination of all detectable plasma arginine in patients with metastatic melanoma was well tolerated and may be effective in the treatment of this cancer. Further testing of ADI-SS PEG 20,000 mw in a larger population of individuals with metastatic melanoma is warranted.

UR - http://www.scopus.com/inward/record.url?scp=32944469353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32944469353&partnerID=8YFLogxK

U2 - 10.1200/JCO.2005.02.0933

DO - 10.1200/JCO.2005.02.0933

M3 - Article

VL - 23

SP - 7660

EP - 7668

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 30

ER -